Skip to content
CFPS Research Archives

Exenatide (Byetta)

FDA-approved context Weight Loss & Metabolism 3 sources

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally derived from the venom of the Gila monster. It is FDA-approved for the treatment of type 2 diabetes, where it helps regulate blood sugar levels and often induces weight loss. Emerging research is also exploring its potential neuroprotective effects in conditions like Parkinson's disease.

01Dosing reference

Amount
5-10 mcg
Frequency
Twice daily (within 60 minutes before morning and evening meals)
Cycle
Continuous use as prescribed for glycemic control
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

GLP-1 Receptor Activation

Exenatide binds to and activates the GLP-1 receptor on pancreatic beta cells and in the central nervous system.

02

Insulin and Glucagon Regulation

It stimulates glucose-dependent insulin secretion while simultaneously suppressing inappropriate glucagon secretion.

03

Gastric Emptying and Satiety

It slows gastric emptying and promotes a feeling of fullness, leading to reduced food intake and improved glycemic control.

03Human evidence

Significant reductions in HbA1c and fasting plasma glucose in patients with type 2 diabetes.

Multiple large-scale randomized controlled trials leading to FDA approval.

Consistent weight loss observed as a secondary effect in diabetic patients.

Clinical trials comparing exenatide to insulin or placebo over 24-30 weeks.

Potential improvements in motor and cognitive symptoms in Parkinson's disease.

Phase 2 clinical trials showing sustained benefits, though larger Phase 3 trials are ongoing to confirm efficacy.

04Preclinical evidence

Neuroprotective and neurorestorative effects in animal models of neurodegeneration.

Rodent models of Parkinson's and Alzheimer's diseases showing reduced neuroinflammation and improved neuronal survival.

Preservation of pancreatic beta-cell mass and function.

In vitro and animal studies demonstrating reduced apoptosis and increased proliferation of beta cells.

05What is known vs. unknown

Reasonably established
  • FDA-approved for improving glycemic control in adults with type 2 diabetes.
  • Promotes weight loss by delaying gastric emptying and increasing satiety.
  • Has a short half-life requiring twice-daily subcutaneous injections (for the Byetta formulation).
  • Derived from exendin-4, a peptide found in Gila monster saliva, which is resistant to rapid degradation by DPP-4.
Unknowns & limits
  • The long-term efficacy and safety of exenatide for neurodegenerative diseases like Parkinson's remain under investigation.
  • May cause gastrointestinal side effects, particularly nausea, which can limit tolerability in some patients.
  • The exact mechanisms by which it exerts neuroprotective effects in the human brain are not fully understood.

06Safety & regulatory context

Regulatory statusExenatide is FDA-approved (as Byetta for twice-daily use and Bydureon for once-weekly use) for type 2 diabetes. Common side effects include nausea, vomiting, diarrhea, and feeling jittery. It carries a warning for the risk of thyroid C-cell tumors (specifically for the extended-release formulation) and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma. It may also increase the risk of acute pancreatitis.

07Compared with Liraglutide

Exenatide (Byetta) vs. Liraglutide
Key difference
Exenatide (Byetta) is a short-acting GLP-1 agonist requiring twice-daily dosing, whereas Liraglutide is a human GLP-1 analog with a longer half-life allowing for once-daily dosing.
When researchers discuss each
Researchers discuss exenatide when focusing on exendin-4 derivatives and early GLP-1 therapies, while liraglutide is often discussed in the context of once-daily dosing and specific FDA approval for obesity.

08Glossary

GLP-1 Receptor Agonist
A class of medications that mimic the action of the naturally occurring hormone GLP-1 to stimulate insulin release and lower blood sugar.
Exendin-4
A 39-amino acid peptide found in the venom of the Gila monster that shares overlapping biological properties with human GLP-1 but has a longer half-life.
Gastric Emptying
The process by which food leaves the stomach and enters the small intestine; slowing this process helps control post-meal blood sugar spikes.

09Knowledge check

Q1What is the primary natural source from which exenatide was originally derived?
Q2Which of the following is a key mechanism of action for exenatide?
Q3Which statement best reflects the current clinical evidence for exenatide's effects on Parkinson's disease as presented in the dossier?
Q4According to the supplied comparison, what is the primary practical dosing-related difference between exenatide (Byetta) and liraglutide that researchers emphasize?
Q5Which safety or regulatory concern about exenatide is explicitly described in the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism
Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism
Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism
Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.